Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS

NACompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

January 26, 2021

Study Completion Date

February 21, 2021

Conditions
Prone PositioningHigh Flow Nasal CannulaAcute Respiratory Distress SyndromeCorona Virus Infection
Interventions
DEVICE

high flow nasal cannula (HFNC)

HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.

PROCEDURE

Prone positioning (PP)

PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors
lead

Rush University Medical Center

OTHER

NCT04325906 - Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS | Biotech Hunter | Biotech Hunter